CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 185 enrolled
Drug / intervention
PegIntron (peginterferon alfa-2b; SCH 54031) pen +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00704717
NCT00704717N/ACompleted
CompareCT.gov

Evaluation of Satisfaction in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C

Merck Sharp & Dohme LLC·observational·Posted Jun 25, 2008·Updated Apr 29, 2015

In Brief

An observational study evaluating PegIntron (peginterferon alfa-2b; SCH 54031) pen and Rebetol (ribavirin; SCH 18908) for Hepatitis C, Chronic and Hepatitis C. Completed, enrolled 185 participants.

Detailed Summary

The objective of this study is to evaluate patient satisfaction in hepatitis C patients receiving PegIntron pen plus Rebetol. The rationale is that the effectiveness of treatment is correlated with adherence to the prescribed regimen which, in turn, is affected by the ease of use and accuracy of treatment administration. Since the PegIntron pen is a novel device, the results of this study will be used to improve the training of patients and healthcare providers in PegIntron pen use.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Hepatitis C
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 25, 2008
Enrollment StartSep 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.0 years ago

Interventions

PegIntron (peginterferon alfa-2b; SCH 54031) penbiological

PegIntron pen administered in accordance with approved labeling

Rebetol (ribavirin; SCH 18908)drug

Rebetol administered in accordance with approved labeling.